Generate a tailored SOP for Dr. Myriam Heiman. Improve your application with a focused, well-structured draft.
Myriam Heiman received her B.A. in Molecular Biology from Princeton University and a Ph.D. in Biology from Johns Hopkins University. Following her education, she completed post-doctoral training at Rockefeller University, where she worked with Dr. Paul Greengard and Dr. Nathaniel Heintz. In 2011, she established her research group at the Massachusetts Institute of Technology's Picower Institute for Learning and Memory. Her research focuses on common neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s diseases, which are characterized by distinct clinical presentations. The aim of her research is to elucidate the basis for the enhanced vulnerability of specific neuronal cell types in these diseases, providing insights into the cell biology of relevant neuronal cell types and identifying new therapeutic targets. Her work employs innovative methods to address long-standing questions regarding enhanced vulnerability, including translating ribosome affinity purification (TRAP) and genome-wide screening in the central nervous system. In recent years, her group has incorporated single-cell sequencing approaches to study the central nervous system and has conducted recent single-cell studies of human cerebrovasculature associated with Huntington’s disease and other neurodegenerative disorders. Dr. Heiman's contributions have been recognized with several awards, including the EURKEA award and the R35 Outstanding Investigator Award from the NIH.
Massachusetts Institute of Technology • Cambridge, MA
Leading research at the Picower Institute focused on neurodegenerative diseases and neuronal vulnerability.